KMS Pharma provides pharmaceutical development services spanning formulation design, preformulation, analytical development, process evaluation and technology transfer. The development approach is shaped by the molecule, dosage form, product quality requirements and intended manufacturing route.
When comparing a formulation development company in Chennai, pharmaceutical businesses should consider how formulation decisions will translate into reproducible processes, relevant stability data and technical documentation. A formulation that performs at laboratory scale must also be evaluated for its suitability for further development and manufacturing.
Pharmaceutical Formulation Development Company in Chennai
Pharmaceutical formulation development turns the properties of an active pharmaceutical ingredient (API) into a dosage form designed around defined product requirements. The work may involve selecting excipients, evaluating compatibility, understanding material characteristics and establishing a suitable manufacturing process.
KMS Pharma applies a structured development approach for complex and differentiated products. Quality by Design and Design of Experiments can help identify important formulation variables, understand interactions and establish process ranges supported by experimental data.
The work begins with the product's target profile and the available scientific information. Formulation and process risks are then considered alongside analytical requirements, stability expectations and the practical needs of scale-up. The exact programme depends on the product and its stage of development.
Define the target product profile and relevant critical quality attributes.
Characterise the API and assess drug–excipient compatibility.
Evaluate formulation and process risks using a science-based approach.
Generate development data to guide stability assessment and scale-up planning.
9 oral solid process technologies
A range of process technologies supports the development of tablets, capsules, granules, coated products and other oral solid dosage forms.
15 sterile formats
Development capabilities span a range of sterile product formats, including injectable, ophthalmic and specialised parenteral systems.
QbD and DoE
Structured risk assessment and experimental design help evaluate formulation variables and support evidence-based development decisions.
How pharmaceutical formulation development works
A formulation programme is built around the molecule and the intended product. Each stage generates information that helps guide the next decision, from early material assessment to pilot-scale processing. The activities may overlap or be adapted to suit the development pathway.
Landscape and requirements review
Review relevant patents, scientific literature, compendial requirements and available product information before selecting a development approach.
Target product profile
Define the quality target product profile and identify critical quality attributes that influence the intended product characteristics.
Formulation and process risk assessment
Evaluate potential risks associated with the molecule, excipients, dosage form and manufacturing process.
Preformulation studies
Characterise relevant API properties and assess drug–excipient compatibility to inform formulation selection.
Design of Experiments and optimisation
Use DoE where appropriate to study variable interactions, assess formulation options and identify robust operating ranges.
Stability assessment
Generate and review development stability data using an appropriate study design informed by the product and applicable ICH guidance.
Pilot-scale process development
Evaluate how the formulation performs using relevant process equipment and identify considerations for further scale-up and manufacturing.
The outcome is a documented understanding of the formulation and process, supported by the studies performed. Additional work may be required before technology transfer, commercial manufacture or regulatory submission, depending on the project.
Oral solid formulation development in Chennai
Tablets, hard and soft gelatin capsules, and powders for oral solutions or suspensions each have different formulation and processing requirements. The development route depends on properties such as API solubility, particle size, compressibility, stability and the intended product performance.
A suitable process must account for both formulation characteristics and manufacturing behaviour. Granulation, compression, coating, milling and encapsulation may be considered according to the product's needs rather than applied as a fixed sequence.
Wet and dry granulation
Wet granulation, dry granulation and roller compaction may be evaluated where powder properties and product requirements support their use.
Functional coating and Wurster processing
Top-spray granulation, Wurster coating and functional or non-functional coating of pellets and tablets support different processing objectives.
Compression and capsule filling
Multilayer compression, capsule filling and related process options can be considered according to the dosage form and formulation.
Particle-size reduction
Air-jet milling can be evaluated when API particle-size characteristics need to be adjusted for a defined development objective.
Extrusion and spheronisation
Pelletisation and subsequent coating may be appropriate for products requiring specific multiparticulate or release characteristics.
Product-specific manufacturing routes
The process is selected after considering formulation properties, target attributes, equipment requirements and the intended development scale.
KMS Pharma's stated capabilities include nine oral solid process technologies. The selection of equipment and processing methods for an individual project should be confirmed against the product's requirements.
Oral liquid and semi-solid formulation development
Oral liquids and semi-solid formulations serve product requirements that differ from those of conventional tablets and capsules. Solutions, suspensions, concentrates, creams and topical gels require suitable choices for composition, physical characteristics, handling and stability.
In selected projects, formulation development may involve converting an existing tablet-based product into an oral liquid for patients who have difficulty swallowing solid dosage forms. Such a change requires an appropriate technical assessment of the formulation, dose delivery, product characteristics and stability.
Oral solutions: Consider API solubility, formulation composition and relevant product characteristics.
Oral suspensions: Evaluate dispersion, physical stability and other attributes relevant to the intended product.
Ready-to-use suspensions and concentrates: Define appropriate formulation and use requirements for the proposed product.
Creams and topical gels: Assess composition, physical properties and stability according to the intended application.
The appropriate development route depends on the drug substance, dosage form and product objectives. Formulation changes should be supported by relevant data rather than assumed to perform identically to the original dosage form.
Sterile formulation development for injectable and ophthalmic products
Sterile products require careful consideration of formulation composition, product quality, container-closure systems, stability and the intended method of administration. Reconstitution behaviour and the properties of the active ingredient can also influence formulation design.
KMS Pharma's stated development portfolio covers 15 sterile formats. The relevant formulation and process requirements vary between conventional aqueous solutions, complex dispersed systems, lyophilised products and specialised delivery formats.
Aqueous and non-aqueous injections
Formulation considerations depend on API properties, excipient selection, intended administration and the requirements of the proposed product.
Emulsions and nanosuspensions
Micro-emulsions, nano-emulsions, nano-suspensions and macro-suspensions require product-specific evaluation of their physical and chemical characteristics.
Freeze-dried formulations
Lyophilised products require evaluation of formulation composition, processing considerations, storage stability and reconstitution characteristics.
Pre-filled syringes and infusion bags
Container compatibility, product characteristics and the intended delivery system form part of the development assessment.
Ophthalmic solutions and suspensions
Ophthalmic solutions, emulsions and suspensions require consideration of their intended use and applicable product quality requirements.
Liposomes and microspheres
Specialised delivery systems may require additional formulation and characterisation work based on the molecule and product design.
Other stated formats include powders for solution for injection. The exact scope, facilities and development activities available for a particular sterile product should be confirmed with KMS Pharma.
Formulation development for complex pharmaceutical molecules
Some molecules present formulation challenges that require more than a conventional development approach. Solubility, stability, compatibility, delivery requirements and process sensitivity can affect the choice of formulation and the studies needed to understand product behaviour.
KMS Pharma's stated development areas include the product classes below. Each class has distinct scientific and manufacturing considerations, so the development strategy should be tailored to the molecule and intended dosage form.
Non-β-lactam products
Formulation and process development can be planned around the properties of the active ingredient and the requirements of the intended product.
Atypical β-lactams
The stated portfolio includes imipenem, ertapenem and meropenem. Product-specific requirements determine the relevant formulation and process considerations.
Protein and peptide products
These molecules may require particular attention to formulation compatibility, stability and the conditions used during processing and storage.
Anti-cancer products
Development requirements depend on the molecule, intended delivery system, dosage form and applicable quality and handling requirements.
Hormone formulations
Formulation selection and development studies should reflect the API's properties and the intended product characteristics.
Specialised product programmes
The stated areas also include biosimilar injections, 505(b)(2) sterile products and new chemical entity (NCE) clinical formulations.
Development scope differs between products and regulatory pathways. Clinical, regulatory and manufacturing activities should be defined separately according to the project rather than assumed to be included in every formulation programme.
Drug delivery technologies for differentiated formulations
When a conventional dosage form does not meet a product's requirements, an alternative drug delivery platform may be worth evaluating. Platform selection depends on the molecule, intended route of administration, desired product characteristics and evidence generated during development.
Orally disintegrating films (ODF)
Thin films are designed to disintegrate in the mouth. Their development involves consideration of composition, film properties, drug distribution and product stability.
Orally disintegrating wafers (ODW)
Wafer-based dosage forms require formulation and process evaluation to establish suitable physical characteristics and performance.
Self-emulsifying drug delivery systems (SEDDS)
These systems may be explored for selected poorly water-soluble, lipophilic compounds where improving oral drug solubilisation is a development objective.
Pelletisation with enteric coating
Pelletisation and enteric coating can be evaluated when the intended product requires protection under particular conditions or a specific release profile.
A drug delivery platform is selected based on scientific suitability, not simply because a technology is available. Formulation performance, stability, process feasibility and the requirements of the intended product all inform the decision.
Formulation development equipment and process capabilities
Development and pilot-scale equipment helps assess how a formulation behaves under relevant processing conditions. It can support process selection, equipment-related evaluation and preparation for further scale-up. The equipment used for each project depends on the dosage form and the proposed manufacturing route.
The equipment details provided for KMS Pharma include the following systems. Confirm the equipment's current availability and suitability for a specific project before finalising the development scope.
Fluid bed processor
ACG fluid bed processor with top-spray and Wurster columns for relevant granulation and coating processes.
Roll compactor
Equipment for evaluating dry granulation and roller compaction where the formulation and process requirements support this approach.
Extruder and spheroniser
Fuji Paudal extruder and spheroniser for applicable extrusion and pelletisation development work.
Rotary tablet presses
Cadmach 17-station and Karnavati 10-station rotary presses with D and B tooling, as specified in the equipment list.
Tablet coating systems
Neocota auto-coater and a conventional coating pan for relevant coating process development.
Capsule filling machine
MF 300 encapsulation machine for applicable capsule formulation and processing requirements.
Particle-size reduction equipment
Air-jet mill and multi mill for relevant milling and material-processing operations.
Blending equipment
Octagonal blenders of 3 L and 7 L, and double-cone blenders of 3 L and 5 L, as specified in the equipment list.
High-pressure homogeniser
GEA Niro Soavi Panda Plus high-pressure homogeniser for suitable formulation development applications.
Blister packing machine
Blister packing equipment for relevant packaging development and process evaluation requirements.
The combination of formulation knowledge and process equipment can help identify practical development considerations before moving to a larger manufacturing scale. Equipment availability alone does not establish that a specific product or process is validated or ready for commercial production.
How QbD and DoE support pharmaceutical formulation development
Quality by Design (QbD) provides a structured way to develop product and process understanding around predefined quality objectives. Instead of relying only on trial-and-error adjustments, development teams can identify relevant variables, assess risks and use experimental evidence to guide formulation decisions.
Design of Experiments (DoE) is one approach used to study multiple factors and their interactions. Where appropriate, it can help establish which variables have a meaningful influence on selected product attributes and support the evaluation of suitable operating ranges.
Quality target product profile: Define the intended product characteristics and development objectives.
Critical quality attributes: Identify the product attributes that require assessment.
Risk assessment: Evaluate potential sources of variability in formulation and processing.
Experimental design: Study selected variables and interactions using an appropriate DoE strategy.
Development evidence: Use results to guide formulation selection, process development and subsequent studies.
QbD and DoE do not remove the need for appropriate testing, stability assessment or process evaluation. They provide a systematic framework for generating and using development knowledge.
Formulation stability studies and scale-up planning
A formulation that performs well during initial laboratory development must still be evaluated for stability and manufacturing feasibility. Changes in scale, equipment, processing conditions or materials can affect product characteristics, so these factors need to be considered during process development.
Stability studies generate information about how a product's relevant attributes change over time under defined conditions. The appropriate study design depends on the dosage form, product characteristics, development stage and applicable guidance.
Establish the development baseline
Document the formulation composition, process parameters and relevant product characteristics.
Evaluate stability data
Review available data to understand relevant changes and identify further studies that may be needed.
Assess process performance
Consider mixing, granulation, compression, coating or other process requirements relevant to the selected dosage form.
Plan the next development stage
Identify scale-up requirements, analytical needs, documentation gaps and the work needed for technology transfer or regulatory activities.
Scale-up and regulatory filing require product-specific evidence and documentation. The scope and completion of these activities should be defined according to the programme and applicable requirements.
How to choose a pharmaceutical formulation development company in Chennai
Selecting a formulation development partner starts with understanding what the product needs at its current stage. Some projects require early preformulation work, while others need optimisation, a specialised delivery platform, analytical support or pilot-scale process evaluation.
When assessing a pharmaceutical formulation development company in Chennai, consider these practical questions before agreeing on the project scope.
Relevant dosage-form experience: Ask whether the proposed development capabilities match your molecule and intended dosage form.
Scientific approach: Understand how preformulation, risk assessment, QbD and DoE may be applied to your product.
Equipment and scale-up: Confirm the equipment, process capabilities and scale-up activities relevant to the proposed work.
Analytical and stability requirements: Clarify the testing, study design and documentation included in the scope.
Regulatory documentation: Establish which technical documents and regulatory support activities are included and which require separate arrangements.
Project deliverables: Agree on responsibilities, timelines, data outputs, development milestones and the next-stage requirements.
A clear project brief helps a potential partner assess feasibility and identify the work needed. Specific capabilities, certifications, equipment availability, deliverables and timelines should be confirmed directly rather than inferred from general service descriptions.
Discuss your formulation development project
Planning a new formulation, working with a complex molecule or evaluating a specialised dosage form? Contact KMS Pharma to discuss your product requirements, development stage and the formulation, analytical or scale-up activities relevant to your project.
Discuss Your Requirements